| A Message from i2i Marketing Group Dear Investor,
You're about to discover what could become one of the leaders in the race to treat Alzheimer's.
Why?
It's Alzheimer's treatment, is nearing Phase 2 trials and is showing remarkable potential. It's unlike any pill or treatment you've ever heard of.
That's because this company has literally patented a molecule that may not only treat but has been shown to reverse Alzheimer's in early studies.
But this biotech is smart.
Its patented molecules block competitors from creating knockoffs. It's a strategic advantage that could make early investors very happy one day.
With buyouts getting bigger than ever in biotech and Big Pharma spending billions to buyout competitors... now is the time to move this one stock to the top of your watchlist.
Not only that...
With FDA approvals accelerating and the Alzheimer's market growing at 20% annually, this stock could be poised for significant growth.
Take a closer look at this biotech.
This message is a paid advertisement for InMed Pharmaceuticals from i2i Marketing Group. Wealthpire, Inc. has received a fixed fee of $2,500 from InMed Pharmaceuticals for multiple Dedicated Email Sends, and Newsletter Sponsorships. Other than the compensation received for this advertisement sent to subscribers, Wealthpire, Inc. and its principals are not affiliated with either InMed Pharmaceuticals (INM) or i2i Marketing Group. Wealthpire, Inc. and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither Wealthpire, Inc. nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Wealthpire, Inc. to buy or sell any security. Wealthpire, Inc. has not evaluated the accuracy of any claims made in this advertisement. Wealthpire, Inc. recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding InMed Pharmaceuticals (INM) on i2i Marketing Group website for additional information about the relationship between i2i Marketing Group and InMed Pharmaceuticals (INM). |
